An observational study in Gynecologic Cancer, Colorectal Cancer and Pancreatic Cancer, sponsored by Alaunos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Alaunos Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 304th largest by enrollment of the 325 observational ones that give a count, is one of 127 that started in 2022, is one of 326 observational ones, and was the 1,728th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 818 · Phase 2 793 · Phase 3 132 · Phase 4 19
First in 1981; this study’s year is marked. 127 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 1,934 interventional studies, 220 across the 325 observational. Of the 1,566 that completed or were terminated, 551 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
887 of 2,342 have an industry lead sponsor. The 10 most frequent:
Alaunos Therapeutics is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Alaunos Therapeutics has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
226 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Add all 226 to your calendar (.ics) → With an account.
Among the 2,342 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors
This is a prospective observational, non-interventional study for the long-term follow-up of safety and efficacy for subjects who have received autologous T cells engineered using the Sleeping Beauty System to express T cell receptors (TCRs) reactive against cancer-specific mutations (neoantigen specific TCR-T cells). In this study, subjects will be followed for up to 15 years after initial TCR-T cell drug product administration for evaluation of delayed adverse events (AEs).
Follow-up ended after 7 deaths were reported; 1 participant met the study criteria for lack of cell persistence. No participant remained in follow-up at the 06 July 2025 reporting cutoff.
Patients will be enrolled following either the completion or early termination/discontinuation from Study NCT05194735 or any protocol in which patients were administered Neoantigen specific TCR-T cell drug product. Patients will begin the long-term follow-up period regardless of whether they responded to treatment or progressed on treatment. Patients will be followed for up to 15 years post TCR-T cell drug product infusion and will continue to be monitored for safety, immunogenicity and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Subjects that were consented to this LTFU study but did not receive TCR-T cell drug product on study TCR001-201 will be excluded. No other exclusions are permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in any Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product interventional studies. Patients will be followed for up to 15 years after dosing of Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product.
Biological: Neoantigen specific TCR-T cell drug product
No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy
To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells
Incidence and duration of new related adverse events
Time frame: Up to 2 years post TCR-T cell drug product infusion
To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells
* Incidence and duration of events of special interest, new Serious Adverse Events and new malignancies. * Incidence and duration of late onset adverse events * Proportion of subjects with adverse events leading to death * Incidence of subjects with resolution of adverse events/ serious adverse events and duration of events that began in study TCR001-201 or other clinical trial in which TCR-T cell drug product has been administered.
Time frame: Up to 15 years post TCR-T cell drug product infusion
To investigate translational hypotheses related to TCR-T cell persistence.
Duration of TCR-T cell drug product persistence by vector copy number (VCN).
Time frame: Up to 15 years post TCR-T cell drug product infusion
To determine overall survival.
Date of TCR-T cell drug product administration to death
Time frame: Up to 15 years post TCR-T cell drug product infusion
To continue the clinical efficacy assessment of TCR-T cell product.
Overall response by RECIST 1.1 for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies
Time frame: Up to 15 years post TCR-T cell drug product infusion
To continue the clinical efficacy assessment of TCR-T cell product.
Overall response by iRECIST for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies
Time frame: Up to 15 years post TCR-T cell drug product infusion
To continue the clinical efficacy assessment of TCR-T cell product.
Duration of response (DoR) for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies
Time frame: Up to 15 years post TCR-T cell drug product infusion
To continue the clinical efficacy assessment of TCR-T cell product.
Progression-free survival (PFS) for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
Primary and secondary malignancy: presence of TCR-T cells in tumor samples biopsy and autopsy.
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
Determine the TCR-T persistence, defined by the duration of TCR-T cell drug product measurable by vector copy number (VCN) in peripheral blood samples
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
Transposon insertion-site clonality in TCR-T cells over time.
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
To evaluate changes in T cell infiltration that may occur within the tumor associated with disease progression following TCR-T cell infusion
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
To evaluate infiltration of TCR-T cells within tumor tissue following disease progression
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
To evaluate the presence of HLA alleles within the tumor associated with disease progression following TCR-T cell infusion
Time frame: Up to 15 years post TCR-T cell drug product infusion
To evaluate the long-term profile of persisting TCR-T cells.
To evaluate changes in the presence of tumor-specific neoantigens within the tumor associated with disease progression following TCR-T cell infusion
Time frame: Up to 15 years post TCR-T cell drug product infusion
Ran from Oct 2022 to primary completion in Apr 2025, 30 months.
Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 30 months is below that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Mar 2023 → Oct 2022, primary completion May 2025 → Apr 2025 and completion May 2025 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.